Autoimmune retinopathy associated with carcinoid tumour of the small bowel

Ogra, Siddharth; Sharp, Dianne; Danesh‐Meyer, Helen V.

doi:10.1016/j.jocn.2013.07.002

Cited by 14 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CAR was first described by Sawyer et al 8 as a paraneoplastic syndrome culminating in an AIR. It is most commonly associated with small-cell lung carcinoma,9 colonic tumours10 and gynaecological tumours11 12 and in 50% of patients presenting with symptoms prior to the diagnosis of malignancy.…”

Section: Discussionmentioning

confidence: 99%

Cancer-associated retinopathy in ampullary pancreatic cancer

2019

View full text Add to dashboard Cite

A 64-year-old woman presented with bilateral visual loss with shimmering photopsias as the only clinical manifestation of an occult pancreatic ampullary adenocarcinoma causing duct dilatation. Abnormal electroretinograms led to suspicion of cancer-associated retinopathy (CAR), and CT of the abdomen showed an underlying pancreatic malignancy, detected with subclinical liver function tests following diagnosis of CAR. Biopsy showed a T2N0M0 ampullary adenocarcinoma. The patient was managed with Whipple’s procedure and adjuvant chemotherapy and has made a good recovery with no progression of her retinopathy. To our knowledge, this is one of the first descriptions of CAR in the context of pancreatic malignancy. It is atypical in its asymmetric presentation and favourable patient outcome. CAR is an important diagnosis to make, as ocular manifestations can be the only indication of an occult malignancy, resulting in a swifter diagnosis and potentially life-saving early intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

Cancer-associated retinopathy in ampullary pancreatic cancer

2019

View full text Add to dashboard Cite

show abstract

“…As a corollary, clinical symptoms and signs may change over time due to the secreted peptides (33). Additionally, NETs may secrete substances not related to their cell of origin, such as cytokines and autoantibodies which result in paraneoplastic syndromes (34,35). Although a few of the secreted compounds may be used more generally, there is no ideal NET marker, and the clinician needs to make a choice according to the clinical presentation keeping in mind that the sensitivity and specificity of serum levels differ for each marker.…”

Section: Epidemiology and Classificationmentioning

confidence: 99%

The Diagnosis of Neuroendocrine Tumours: An Endocrine Perspective

Çakır¹,

Grossman²

2018

Turk J Endocrinol Metab

View full text Add to dashboard Cite

“…[40][41][42] Autoantibodies targeting various other retinal proteins have also been implicated as putative causative agents based on the identification of these antibodies in the serum of patients with presumed AIR. These include antibodies against carbonic anhydrase II (which is abundant in ocular tissues) 17,43,44 and the retina-specific tubby-like protein 1 (TULP1). 45 The mere presence of autoantibodies in patient sera does not imply pathogenicity, as the antibodies could represent either "the secondary consequence of tissue damage, or the harmless footprint of an etiologic agent."…”

Section: Antiretinal Antibodies: Pathogenic Uncertaintiesmentioning

confidence: 99%

“…Autoantibodies against the ubiquitous glycolytic enzymes α-enolase, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and aldolase have been implicated in the pathogenesis of AIR in several reports. 43,[47][48][49][50] However, other systemic autoimmune phenomena have not consistently been described in association with these autoantibodies. If these antiretinal antibodies are truly pathogenic, then it is unclear why their toxicity would be specific to the retina when their targets are ubiquitous.…”

Section: Antiretinal Antibodies: Pathogenic Uncertaintiesmentioning

confidence: 99%